Advantage Alpha Capital Partners LP Krystal Biotech, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $299 Million
- Q3 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 2,387 shares of KRYS stock, worth $492,103. This represents 0.14% of its overall portfolio holdings.
Number of Shares
2,387
Previous 2,894
17.52%
Holding current value
$492,103
Previous $397,000
6.05%
% of portfolio
0.14%
Previous 0.12%
Shares
4 transactions
Others Institutions Holding KRYS
# of Institutions
325Shares Held
25MCall Options Held
241KPut Options Held
625K-
Black Rock Inc. New York, NY3.95MShares$814 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.79MShares$576 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.78MShares$573 Million6.7% of portfolio
-
State Street Corp Boston, MA1.4MShares$288 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.02MShares$210 Million10.94% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $5.29B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...